What patient education points are important to convey to patients starting ixekizumab?
Featuring:
Updated:Aug 18, 2026
DermInsider consists of regularly scheduled CME sessions on a variety of dermatological diseases, delivered by the top experts in dermatology. Please join us for this week's session:Wednesday, September 23, 20268 PM ET / 5 PM PTSession 5: Modern Management of Vitiligo: Exploring Current and Future Therapies
2026 Congress of Clinical Rheumatology Rheum-Derm Summit: Skin Signals: Cutaneous Lupus Erythematosus Manifestations and Management. Participate in the live Q&A: https://app.sli.do/event/pAnKunbijgQSY8BWeDQxDvThis symposium explores the diverse clinical manifestations of cutaneous lupus erythematosus (CLE) and their implications for diagnosis, prognosis, and treatment. Through expert discussion, Dr. Vleugels and Dr. Prenner will examine CLE subtypes and their associations with systemic disease, strategies for recognizing manifestations across diverse skin tones, and practical considerations for individualized treatment selection. The program will also highlight emerging clinical evidence on targeted therapies that may expand treatment options and improve outcomes for patients with CLE.This activity is supported by an educational grant from Biogen.
DermInsider Session 4: Progress Through Precision: Leveraging IL-13 Insights to Personalize Atopic Dermatitis Care: An Online ActivityThis activity is supported by an educational grant from Lilly.
In the first DermInsider - A Virtual Grand Rounds Series session of the year, join leading experts Dr. Bhutani and Dr. Serota for a dynamic deep dive into one of the most exciting frontiers in psoriatic disease management. Dr. Del Rosso moderates this 45-minute activity that explores the rapidly emerging role of glucagon-like peptide-1 receptor agonists (GLP-1RAs) and their potential impact beyond metabolic disease. Don't miss out on this opportunity to catch up on breakthrough insights and emerging evidence on this hot topic!“We have some really interesting data on the horizon that’s going to hopefully help more providers feel confident about using [GLP-1] medications in conjunction with their psoriasis medications that they are used to using.” – Tina Bhutani, MD MASBest of FC25: GLP-1RAs in Psoriasis – Catching Up on The ScienceThis activity is supported by an educational grant from Lilly.